GO
Loading...

Bristol-Myers Squibb Co

More

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106- billion takeover approach on Tuesday by predicting its sales would rise by three quarters over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • LONDON, May 6- AstraZeneca Plc laid out its defence against Pfizer Inc's $106 billion takeover approach on Tuesday by predicting its revenues would rise 75 percent over the next decade, although only after a short-term drop. "These are benefits that should fully accrue to AstraZeneca's shareholders."

  • Lightning Round: Valero, Plug Power & More Monday, 5 May 2014 | 6:48 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning Round: NuStar Energy, Hilton & More Friday, 2 May 2014 | 6:48 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • April 29- Bristol-Myers Squibb Co reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, but sparked concerns over a possible delay in completing its marketing application for a high-profile cancer drug.

  • April 29- Bristol-Myers Squibb Co reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, but sales missed Wall Street estimates, and the U.S. drugmaker's shares fell. The company on Tuesday said it had earned $937 million, or 56 cents per share, in the first quarter, compared with $609 million, or 37 cents per share, a year earlier.

  • Wall Street to eye earnings parade, Merck higher Tuesday, 29 Apr 2014 | 9:03 AM ET

    U.S. stock index futures pointed to a higher open, ahead of first quarter earnings from companies including Twitter and eBay.

  • This is what's fueling Pfizer's M&A campaign Tuesday, 29 Apr 2014 | 7:42 AM ET

    At the heart of Pfizer's pursuit of AstraZeneca is a shortage of products in its research pipeline, aggravated by a series of disappointing drug launches.

  • Prescription for pharma profits: Go big Monday, 28 Apr 2014 | 6:51 PM ET

    Argus Research's John Eade weighs in on growing M&A in the pharma space.

  • These are America's fastest shrinking companies Monday, 28 Apr 2014 | 2:35 PM ET

    These companies have been shrinking either due to dropping demand, evaporating pricing power or by reducing their size.

  • Earnings, econ data loom, but the real worry is this Monday, 28 Apr 2014 | 6:28 AM ET
    Traders on the floor of the New York Stock Exchange.

    Investors will navigate a Fed meeting, an earnings flood, and significant economic data, but traders agree global tensions will continue to dominate the market.

  • Pfizer-AstraZeneca deal? Not as crazy as it sounds Monday, 21 Apr 2014 | 6:24 PM ET
    Cholesterol drugs, Crestor, left, manufactured by AstraZeneca Plc, and Lipitor, manufactured by Pfizer Inc.

    There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.

  • AstraZeneca cancer pipeline likely draw for Pfizer Monday, 21 Apr 2014 | 6:16 PM ET
    A Pfizer technician as she works at Neusentis Ltd.'s research laboratory, a unit of Pfizer Inc., in Cambridge, U.K., on Thursday, Sept. 26, 2013.

    Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.

  • Value stocks to stay in vogue, as momentum fades Monday, 21 Apr 2014 | 5:41 PM ET

    With the wipeout in growth stocks, many investors turned their attention to big-cap and value names, and the trend is expected to continue.

  • AstraZeneca cancer pipeline seen as draw for Pfizer Monday, 21 Apr 2014 | 6:55 AM ET

    LONDON, April 21- Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.

  • ZURICH, April 15- A strong uptake of new cancer medicines helped Roche to limit a decline in first-quarter sales and the Swiss company confirmed a forecast for higher earnings this year.

  • LOS ANGELES/ LONDON April 11- Doctors at a key medical conference welcomed the prospect of more new drugs to treat the liver-destroying hepatitis C virus, while agreeing that Gilead Sciences Inc continues to lead the effort.

  • WASHINGTON, April 10- The leading U.S. pharmaceutical industry trade group on Thursday defended the cost of Gilead Sciences Inc's new hepatitis C drug, Sovaldi, saying such treatments offer a priceless breakthrough for patients with the liver-destroying virus.

  • April 10- A combination of two anti-viral drugs developed by Bristol-Myers Squibb Co cured 90 percent of previously untreated hepatitis C patients and 82 percent of those who failed to respond to prior therapy, according to results from a late stage study presented on Thursday.

  • April 10- A two-drug combination being tested by Merck& Co to treat hepatitis C cured 98 percent of previously untreated patients without cirrhosis in a midstage clinical trial, providing the latest evidence that the U.S. drugmaker will be highly competitive in the fast evolving field.